Drug Profile
RVT 301
Alternative Names: RVT-301Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Roivant Sciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glycogen storage disease type I; Glycogen storage disease type II
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for phase-I development in Glycogen-storage-disease-type-I in Unknown
- 28 Oct 2019 No recent reports of development identified for phase-I development in Glycogen-storage-disease-type-II in Unknown
- 09 Sep 2016 Roivant Sciences and Duke University agree to co-develop RVT 301 for glycogen storage disorders and orphan paediatric disorders (Roivant Sciences website, September 2016)